Skip to main content
Top
Published in: Health and Quality of Life Outcomes 1/2015

Open Access 01-12-2015 | Research

Construction of quality of life change patterns: example in oncology in a phase III therapeutic trial (FFCD 0307)

Authors: Gillles Nuemi, Hervé Devilliers, Karine Le Malicot, Rosine Guimbaud, Côme Lepage, Catherine Quantin

Published in: Health and Quality of Life Outcomes | Issue 1/2015

Login to get access

Abstract

Objective

Quality of life data in cancerology are often difficult to summarize due to missing data and difficulty to analyze the pattern of evolution in different groups of patients. The aim of this work was to apply a new methodology to construct Quality of Life (QoL) change patterns within patients included in a clinical trial comparing to regimen of treatment in locally advanced eosogastric cancer.

Materials and methods

In this trial, QoL was assessed every 2 months by self-reported EORTC QLQ-C30 questionnaire. Physical dimension scores were analyzed. After multiple imputation of missing data, 27 statistical measures aiming to describe the variation of QoL measures among follow-up were computed for each patient. Based on these measures, patient were grouped into homogenous groups in terms of QoL variation pattern using a K-Means classification method. The mean QoL score at each time was graphically represented in each obtained pattern. Finally, clinical characteristic of patients in each pattern of QoL were described and compared.

Results

The trial included 416 patients and 1023 questionnaire were collected. 74 % of patients were male with a mean ± SD age of 62 ± 11 years. 43 % of scores were missing. Patients were grouped into four classes of homogeneous QoL variation patterns. 1) a Pattern of 24 (6 %) patients showing improvement in QoL with a mean variation of +10.7 points on the 0–100 scale, 2) a Pattern of 171 (41 %) patients showing a stability 3) two Patterns of 78 (19 %) and 143 (34 %) patients respectively showing a deterioration of QoL with a mean variation of −67.2 and −67.6, respectively. There were no difference between patterns in terms of gender or age. Patients within “degradation” pattern had significantly lower performance status (p = 0.015), higher severe after-effects rate (p < 10-3) and death rate (p < 10-3).

Conclusion

This work opens up perspectives for longitudinal data analysis with a high probability of missing values while providing a relevant graphical summary. Patterns of QoL evolution with clinical relevance may help to interpret longitudinal QoL data in Cancer studies.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bouvier AM, Remontet L, Jougla E, Launoy G, Grosclaude P, Buemi A, et al. Incidence of gastrointestinal cancers in France. Gastroenterol Clin Biol. 2004;28(10 Pt 1):877–81.CrossRefPubMed Bouvier AM, Remontet L, Jougla E, Launoy G, Grosclaude P, Buemi A, et al. Incidence of gastrointestinal cancers in France. Gastroenterol Clin Biol. 2004;28(10 Pt 1):877–81.CrossRefPubMed
2.
go back to reference Remontet L, Esteve J, Bouvier AM, Grosclaude P, Launoy G, Menegoz F, et al. Cancer incidence and mortality in France over the period 1978–2000. Rev Epidemiol Sante Publique. 2003;51(1 Pt 1):3–30.PubMed Remontet L, Esteve J, Bouvier AM, Grosclaude P, Launoy G, Menegoz F, et al. Cancer incidence and mortality in France over the period 1978–2000. Rev Epidemiol Sante Publique. 2003;51(1 Pt 1):3–30.PubMed
3.
go back to reference Moinpour C, Donaldson G, Liepa A, Melemed A, O’Shaughnessy J, Albain K. Evaluating health-related quality-of-life therapeutic effectiveness in a clinical trial with extensive nonignorable missing data and heterogeneous response: results from a phase III randomized trial of gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer. Qual Life Res. 2012;21(5):765–75.CrossRefPubMed Moinpour C, Donaldson G, Liepa A, Melemed A, O’Shaughnessy J, Albain K. Evaluating health-related quality-of-life therapeutic effectiveness in a clinical trial with extensive nonignorable missing data and heterogeneous response: results from a phase III randomized trial of gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer. Qual Life Res. 2012;21(5):765–75.CrossRefPubMed
4.
go back to reference Curran D, Pozzo C, Zaluski J, Dank M, Barone C, Valvere V, et al. Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial. Qual Life Res. 2009;18(7):853–61.PubMedCentralCrossRefPubMed Curran D, Pozzo C, Zaluski J, Dank M, Barone C, Valvere V, et al. Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial. Qual Life Res. 2009;18(7):853–61.PubMedCentralCrossRefPubMed
5.
go back to reference Sadighi S, Mohagheghi MA, Montazeri A, Sadighi Z. Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF). BMC Cancer. 2006;6:274.PubMedCentralCrossRefPubMed Sadighi S, Mohagheghi MA, Montazeri A, Sadighi Z. Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF). BMC Cancer. 2006;6:274.PubMedCentralCrossRefPubMed
6.
go back to reference Gotay CC. Assessing cancer-related quality of life across a spectrum of applications. J Natl Cancer Inst Monogr. 2004;33:126–33.CrossRefPubMed Gotay CC. Assessing cancer-related quality of life across a spectrum of applications. J Natl Cancer Inst Monogr. 2004;33:126–33.CrossRefPubMed
7.
go back to reference Young T, deHaes H, Curran D. Guidelines for assessing quality of life in EORTC Clinical Trials Brussels EORTC quality of life group 2004. Young T, deHaes H, Curran D. Guidelines for assessing quality of life in EORTC Clinical Trials Brussels EORTC quality of life group 2004.
8.
go back to reference Beitz J, Gnecco C, Justice R. Quality-of-life end points in cancer clinical trials: the US Food and Drug Administration perspective. J Natl Cancer Inst Monogr. 1996;20:7–9.PubMed Beitz J, Gnecco C, Justice R. Quality-of-life end points in cancer clinical trials: the US Food and Drug Administration perspective. J Natl Cancer Inst Monogr. 1996;20:7–9.PubMed
9.
go back to reference Barbare J, Bouche O, Bonnetain F, Raoul J, Rougier P. Abergel Aea. Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol. 2005;23(19):4338–46.CrossRefPubMed Barbare J, Bouche O, Bonnetain F, Raoul J, Rougier P. Abergel Aea. Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol. 2005;23(19):4338–46.CrossRefPubMed
10.
go back to reference Bedenne L, Michel P, Bouche O, Milan C, Mariette C. Conroy Tea. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25(10):1160–8.CrossRefPubMed Bedenne L, Michel P, Bouche O, Milan C, Mariette C. Conroy Tea. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25(10):1160–8.CrossRefPubMed
11.
go back to reference Curran D, Molenberghs G, Fayers PM, Machin D. Incomplete quality of life data in randomized trials: missing forms. Stat Med. 1998;17(5–7):697–709.CrossRefPubMed Curran D, Molenberghs G, Fayers PM, Machin D. Incomplete quality of life data in randomized trials: missing forms. Stat Med. 1998;17(5–7):697–709.CrossRefPubMed
12.
go back to reference Fayers PM, Curran D, Machin D. Incomplete quality of life data in randomized trials: missing items. Stat Med. 1998;17(5–7):679–96.CrossRefPubMed Fayers PM, Curran D, Machin D. Incomplete quality of life data in randomized trials: missing items. Stat Med. 1998;17(5–7):679–96.CrossRefPubMed
13.
14.
go back to reference Ck E. Applied missing data analysis. 1st ed. New York: Guilford Press; 2010. Ck E. Applied missing data analysis. 1st ed. New York: Guilford Press; 2010.
15.
go back to reference Fairclough DL. Design and analysis of quality of life studies in clinical trials (Second ed.): Chapman and Hall/CRC Press; Boca Raton. 2010. Fairclough DL. Design and analysis of quality of life studies in clinical trials (Second ed.): Chapman and Hall/CRC Press; Boca Raton. 2010.
16.
go back to reference Post WJ, Buijs C, Stolk RP, de Vries EG, le Cessie S. The analysis of longitudinal quality of life measures with informative drop-out: a pattern mixture approach. Qual Life Res. 2010;19(1):137–48.PubMedCentralCrossRefPubMed Post WJ, Buijs C, Stolk RP, de Vries EG, le Cessie S. The analysis of longitudinal quality of life measures with informative drop-out: a pattern mixture approach. Qual Life Res. 2010;19(1):137–48.PubMedCentralCrossRefPubMed
17.
go back to reference Crawford SL, Tennstedt SL, McKinlay JB. A comparison of anlaytic methods for non-random missingness of outcome data. J Clin Epidemiol. 1995;48(2):209–19.CrossRefPubMed Crawford SL, Tennstedt SL, McKinlay JB. A comparison of anlaytic methods for non-random missingness of outcome data. J Clin Epidemiol. 1995;48(2):209–19.CrossRefPubMed
18.
go back to reference Michikazu N, Weimin K. Review of the Methods for Handling Missing Data in Longitudinal Data Analysis. Int J Math Anal. 2011;5(1):1–13. Michikazu N, Weimin K. Review of the Methods for Handling Missing Data in Longitudinal Data Analysis. Int J Math Anal. 2011;5(1):1–13.
19.
go back to reference Willett JB, Singer JD, Martin NC. The design and analysis of longitudinal studies of development and psychopathology in context: statistical models and methodological recommendations. Dev Psychopathol. 1998;10(2):395–426.CrossRefPubMed Willett JB, Singer JD, Martin NC. The design and analysis of longitudinal studies of development and psychopathology in context: statistical models and methodological recommendations. Dev Psychopathol. 1998;10(2):395–426.CrossRefPubMed
20.
go back to reference Nagin D. Group-Based Modeling of Development: Harvard University Press; Cambridge. 2005. 213 p. Nagin D. Group-Based Modeling of Development: Harvard University Press; Cambridge. 2005. 213 p.
21.
go back to reference Leffondre K, Abrahamowicz M, Regeasse A, Hawker G, Badley E. McCusker Jea. Statistical measures were proposed for identifying longitudinal patterns of change in quantitative health indicators. J Clin Epidemiol. 2004;57(10):1049–62.CrossRefPubMed Leffondre K, Abrahamowicz M, Regeasse A, Hawker G, Badley E. McCusker Jea. Statistical measures were proposed for identifying longitudinal patterns of change in quantitative health indicators. J Clin Epidemiol. 2004;57(10):1049–62.CrossRefPubMed
22.
go back to reference Nagin DS, Odgers CL. Group-based trajectory modeling in clinical research. Annu Rev Clin Psychol. 2010;6:109–38.CrossRefPubMed Nagin DS, Odgers CL. Group-based trajectory modeling in clinical research. Annu Rev Clin Psychol. 2010;6:109–38.CrossRefPubMed
23.
go back to reference Shi Q, Mendoza T, Gunn GB, Wang X, Rosenthal D, Cleeland C. Using group-based trajectory modeling to examine heterogeneity of symptom burden in patients with head and neck cancer undergoing aggressive non-surgical therapy. Quality of Life Research. 2013;22(9):2331–9. Shi Q, Mendoza T, Gunn GB, Wang X, Rosenthal D, Cleeland C. Using group-based trajectory modeling to examine heterogeneity of symptom burden in patients with head and neck cancer undergoing aggressive non-surgical therapy. Quality of Life Research. 2013;22(9):2331–9.
24.
go back to reference Little RJ, D'Agostino R, Cohen ML, Dickersin K, Emerson SS, Farrar JT, et al. The Prevention and Treatment of Missing Data in Clinical Trials. N Engl J Med. 2012;367(14):1355–60.PubMedCentralCrossRefPubMed Little RJ, D'Agostino R, Cohen ML, Dickersin K, Emerson SS, Farrar JT, et al. The Prevention and Treatment of Missing Data in Clinical Trials. N Engl J Med. 2012;367(14):1355–60.PubMedCentralCrossRefPubMed
25.
go back to reference Ibrahim JG, Molenberghs G. Missing data methods in longitudinal studies: a review. Test (Madr). 2009;18(1):1–43.CrossRef Ibrahim JG, Molenberghs G. Missing data methods in longitudinal studies: a review. Test (Madr). 2009;18(1):1–43.CrossRef
26.
go back to reference Graham JW. Missing data analysis: making it work in the real world. Annu Rev Psychol. 2009;60:549–76.CrossRefPubMed Graham JW. Missing data analysis: making it work in the real world. Annu Rev Psychol. 2009;60:549–76.CrossRefPubMed
27.
go back to reference Basagana X, Barrera-Gomez J, Benet M, Anto JM, Garcia-Aymerich J. A Framework for Multiple Imputation in Cluster Analysis. Am J Epidemiol. 2013;177(7):718–25.CrossRefPubMed Basagana X, Barrera-Gomez J, Benet M, Anto JM, Garcia-Aymerich J. A Framework for Multiple Imputation in Cluster Analysis. Am J Epidemiol. 2013;177(7):718–25.CrossRefPubMed
28.
go back to reference Little RJA. Modeling the Drop-Out Mechanism in Repeated-Measures Studies. Journal of the American Statistical Association. 1995;90(431):1112–21. Little RJA. Modeling the Drop-Out Mechanism in Repeated-Measures Studies. Journal of the American Statistical Association. 1995;90(431):1112–21.
29.
go back to reference Guimbaud R, Louvet C, Ries P, Ychou M, Maillard E, Andre T, et al. Prospective, Randomized, Multicenter, Phase III Study of Fluorouracil, Leucovorin, and Irinotecan Versus Epirubicin, Cisplatin, and Capecitabine in Advanced Gastric Adenocarcinoma: A French Intergroup (Federation Francophone de Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Cooperateur Multidisciplinaire en Oncologie) Study. J Clin Oncol. 2014;32(31):3520–6.CrossRefPubMed Guimbaud R, Louvet C, Ries P, Ychou M, Maillard E, Andre T, et al. Prospective, Randomized, Multicenter, Phase III Study of Fluorouracil, Leucovorin, and Irinotecan Versus Epirubicin, Cisplatin, and Capecitabine in Advanced Gastric Adenocarcinoma: A French Intergroup (Federation Francophone de Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Cooperateur Multidisciplinaire en Oncologie) Study. J Clin Oncol. 2014;32(31):3520–6.CrossRefPubMed
30.
go back to reference Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205–16.CrossRefPubMed Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205–16.CrossRefPubMed
31.
go back to reference Vickery CW, Blazeby JM, Conroy T, Arraras J, Sezer O, Koller M, et al. Development of an EORTC disease-specific quality of life module for use in patients with gastric cancer. Eur J Cancer. 2001;37(8):966–71.CrossRefPubMed Vickery CW, Blazeby JM, Conroy T, Arraras J, Sezer O, Koller M, et al. Development of an EORTC disease-specific quality of life module for use in patients with gastric cancer. Eur J Cancer. 2001;37(8):966–71.CrossRefPubMed
32.
go back to reference Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.CrossRefPubMed Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.CrossRefPubMed
33.
go back to reference Little R, Yau L. Intent-to-treat analysis for longitudinal studies with drop-outs. Biometrics. 1996;52(4):1324–33.CrossRefPubMed Little R, Yau L. Intent-to-treat analysis for longitudinal studies with drop-outs. Biometrics. 1996;52(4):1324–33.CrossRefPubMed
34.
go back to reference Bonnetain F, Bouche O, Conroy T, Arveux P, Raoul JL, Giovannini M, et al. Longitudinal quality of life study in patients with metastatic gastric cancer. Analysis modalities and clinical applicability of QoL in randomized phase II trial in a digestive oncology. Gastroenterol Clin Biol. 2005;29(11):1113–24.CrossRefPubMed Bonnetain F, Bouche O, Conroy T, Arveux P, Raoul JL, Giovannini M, et al. Longitudinal quality of life study in patients with metastatic gastric cancer. Analysis modalities and clinical applicability of QoL in randomized phase II trial in a digestive oncology. Gastroenterol Clin Biol. 2005;29(11):1113–24.CrossRefPubMed
35.
go back to reference Bonnetain F, Dahan L, Maillard E, Ychou M, Mitry E, Hammel P, et al. Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma. Eur J Cancer. 2010;46(15):2753–62.CrossRefPubMed Bonnetain F, Dahan L, Maillard E, Ychou M, Mitry E, Hammel P, et al. Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma. Eur J Cancer. 2010;46(15):2753–62.CrossRefPubMed
36.
go back to reference Edwin D. Une nouvelle méthode de classification automatique et reconnaissance des formes : la méthode des nuées dynamiques. Revue de Statistique appliquée. 1971;19(2):19–33. Edwin D. Une nouvelle méthode de classification automatique et reconnaissance des formes : la méthode des nuées dynamiques. Revue de Statistique appliquée. 1971;19(2):19–33.
37.
go back to reference Breaban M, Luchian H. A unifying criterion for unsupervised clustering and feature selection. Pattern Recogn. 2011;44(4):854–65.CrossRef Breaban M, Luchian H. A unifying criterion for unsupervised clustering and feature selection. Pattern Recogn. 2011;44(4):854–65.CrossRef
38.
39.
go back to reference Warrens M. On the Equivalence of Cohen’s Kappa and the Hubert-Arabie Adjusted Rand Index. J Classif. 2008;25(2):177–83.CrossRef Warrens M. On the Equivalence of Cohen’s Kappa and the Hubert-Arabie Adjusted Rand Index. J Classif. 2008;25(2):177–83.CrossRef
40.
go back to reference Warrens M. A Formal Proof of a Paradox Associated with Cohen’s Kappa. J Classif. 2010;27(3):322–32.CrossRef Warrens M. A Formal Proof of a Paradox Associated with Cohen’s Kappa. J Classif. 2010;27(3):322–32.CrossRef
41.
go back to reference Nuemi G, Afonso F, Roussot A, Billard L, Cottenet J, Combier E, et al. Classification of hospital pathways in the management of cancer: application to lung cancer in the region of burgundy. Cancer Epidemiol. 2013;37(5):688–96.CrossRefPubMed Nuemi G, Afonso F, Roussot A, Billard L, Cottenet J, Combier E, et al. Classification of hospital pathways in the management of cancer: application to lung cancer in the region of burgundy. Cancer Epidemiol. 2013;37(5):688–96.CrossRefPubMed
Metadata
Title
Construction of quality of life change patterns: example in oncology in a phase III therapeutic trial (FFCD 0307)
Authors
Gillles Nuemi
Hervé Devilliers
Karine Le Malicot
Rosine Guimbaud
Côme Lepage
Catherine Quantin
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2015
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/s12955-015-0342-1

Other articles of this Issue 1/2015

Health and Quality of Life Outcomes 1/2015 Go to the issue